Postpartum Hemorrhage Clinical Trial
Official title:
Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor A Randomized Controlled Study
The third stage is the interval between delivery of the infant and delivery of the placenta.
This stage averages 10 minutes and is considered prolonged if it lasts longer than 30
minutes, placental separation occurs as a result of continued uterine contractions,
continued contractions control blood loss by compression of spiral arteries and also result
in migration of the placenta into the lower uterine segment and then through the cervix.
The intra-umbilical vein injection of 10 IU of oxytocin is recommended as a first line of
treatment for retained placenta. Despite this recommendation, the method has yet to make its
way into routine practice, probably because of the lack of a large substantive randomized
controlled trial, and lingering doubts over which uterotonic to use and at what dosage.
The purpose of this study is to evaluate the effect of intraumbilical vein injection of
oxytocin on reducing the duration of the third stage of labor and the need for manual
delivery of placenta, ,in addition to reduce blood loss during third and fourth stage of
labor and decrease incidence of rtained placenta in comparison with inraumblical injection
of normal saline.
This is a prospective randomized control trial conducted at Ain Shams University Maternity
Hospital. This study included 240 term pregnant women in labor admitted to the labor ward,
They were divided into Two groups :
Group (A):
The experimental group, 10 units of oxytocin will be injected into the umbilical vein at the
most proximal site to the placenta after clamping and cutting of the umbilical cord.
Group (B):
The control group, 1 mL normal saline will be injected into the umbilical vein at the most
proximal site to the placenta after clamping and cutting of the umbilical cord.
This study included 240 term pregnant women in labor admitted to the labor ward, They were
divided into Two groups :
Group (A):
The experimental group, 10 units of oxytocin will be injected into the umbilical vein at the
most proximal site to the placenta after clamping and cutting of the umbilical cord.
Group (B):
The control group, 1 mL normal saline will be injected into the umbilical vein at the most
proximal site to the placenta after clamping and cutting of the umbilical cord.
complete blood count of both groups before and 12 h after delivery.
- The third stage of labor will be actively managed in the two groups by infusion of 20
IU oxytocin in 1 L Ringer's lactate solution at a rate of 100 mL/min, immediately after
delivery of the fetus ( Nankali et al., 2013)..
- In the control group ( B ) , 1 mL normal saline will be injected into the umbilical
vein at the most proximal site to the placenta after clamping and cutting of the
umbilical cord.
- In the experimental group ( A ) , instead of normal saline, 10 IU (1mL) oxytocin will
be injected at the same site. We will wait 30 min for the symptoms of placenta delivery
(i.e., the uterus became firmer and more globular and was displaced upward, a gush of
blood occurred, and the umbilical cord was elongated).
- Spontaneous delivery of the placenta will be achieved by touching the fundus and
applying pressure on the symphysis pubis by a finger and slight traction of the
umbilical cord.
- For each participant, the duration of the third stage of labor (the time period between
the delivery of the fetus and the delivery of the placenta) will be recorded.
- The two groups will be compared in the following terms:
1. The duration of the third stage of labor by stopwatch.
2. Hemoglobin (Hb) difference before and 12 h after delivery.
3. The need for manual delivery of the placenta. Manual removal of the placenta will
be commonly carried out under general sedation in the operating room, if the
placenta will not be delivered 30 min after fetal delivery.
4. Estimate blood loss by Allowable Blood Loss (ABL) (Miller 2000)
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02910310 -
Introduction of UBT for PPH Management in Three Countries
|
N/A | |
Completed |
NCT03344302 -
Oxytocin Administration During Cesarean Section
|
Phase 4 | |
Completed |
NCT02805426 -
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
|
Phase 4 |